Jasveen Sangha, the drug dealer known as the “Ketamine Queen,” was sentenced to 15 years in prison for supplying the drugs that killed “Friends” star Matthew Perry https://t.co/EpFEj7Z7Vn ...

Jasveen Sangha, also known as the “Ketamine Queen,” was sentenced to 15 years in prison for providing the lethal dose of ketamine that ultimately led to “Friends” star Matthew Perry’s death. https://t.co/8GtWYRkMQZ https://t.co/xntGivda54 ...

Ketamine, an operating-room anesthetic also prized as the street drug “K” is now at the heart of a largely unregulated online industry offering depression relief. https://t.co/lHh75eL3xo ...

Ketamine, an operating-room anesthetic also prized as the street drug “K” is now at the heart of a largely unregulated online industry offering depression relief. https://t.co/lTU96EUyJH https://t.co/2scM0f84b5 ...

Ketamine, an operating-room anesthetic also prized as the street drug “K” is now at the heart of a largely unregulated online industry offering depression relief. https://t.co/lTU96EUyJH https://t.co/1VquIKk1gt ...

Ketamine, an operating-room anesthetic also prized as the street drug “K” is now at the heart of a largely unregulated online industry offering depression relief. https://t.co/lTU96EUyJH https://t.co/m3qoPWImAC ...

Core Viewpoint - Clearmind Medicine Inc. has announced the publication of six patents in Hong Kong, focusing on innovative combination therapies that integrate Palmitoylethanolamide (PEA) with various psychedelic compounds to address under-treated health issues [1][2][3] Group 1: Patent Publication and Innovations - The newly published patents protect formulations that combine PEA with MDMA, LSD, Ketamine, Ibogaine, Psilocybin, and DMT, aiming to enhance therapeutic potential and improve safety and tolerability for mental health and neurological conditions [2] - The company currently holds a total of nineteen patent families, which include 31 granted patents, and plans to seek additional patents as opportunities arise [5] Group 2: Company Strategy and Objectives - Clearmind is focused on developing non-hallucinogenic, neuroplastogen-derived therapeutics to tackle significant health problems, including alcohol use disorder [4] - The CEO emphasized the strategic combination of PEA with well-characterized psychedelics to build a robust pipeline of next-generation candidates aimed at addressing unmet needs in mental health [3]

Ketamine, an operating-room anesthetic also prized as the street drug “K” is now at the heart of a largely unregulated online industry offering depression relief. https://t.co/lHh75eL3xo ...

'Ketamine Queen' spiralled before Matthew Perry death, friends tell BBC https://t.co/0kRxc5xvfe ...

Core Viewpoint - PharmaTher Holdings Ltd. is advancing its ketamine program for treating levodopa-induced dyskinesia (LID-PD) in Parkinson's disease patients, aiming for a Phase 3 clinical study to support a New Drug Application (NDA) [1][2][16] Development Strategy - The company is utilizing the 505(b)(2) regulatory pathway to leverage existing scientific evidence and FDA-reviewed Chemistry, Manufacturing and Controls (CMC) to minimize development risks, costs, and timelines [2][6] - A Phase 3 clinical study is being prepared to evaluate the efficacy and safety of ketamine for LID-PD, pending FDA feedback [2][10] Mechanism and Clinical Evidence - Ketamine's mechanism as a non-competitive NMDA receptor antagonist provides a strong biological rationale for its evaluation in LID-PD, given the involvement of excessive glutamatergic/NMDA signaling in dyskinesia [4] - Previous Phase I/II studies indicated that ketamine was safe and well-tolerated, with significant reductions in dyskinesias observed: 51% reduction during Infusion 2, 49% at 3 weeks, and 41% at 3 months [5] Market Opportunity - The U.S. market opportunity for a ketamine-based treatment in LID-PD is estimated between $0.75 billion and $2.2 billion, based on the prevalence of dyskinesia among Parkinson's patients [12] - Approximately 1.1 million individuals in the U.S. have Parkinson's disease, with 30-40% developing dyskinesia, leading to a potential treated population of 330,000 to 440,000 [11][12] Strategic Significance - The LID-PD program represents a high-value opportunity in a validated treatment category, supported by proprietary clinical data and patent protection until 2036 [13] - The company is engaged in discussions with potential pharmaceutical partners to enhance capital efficiency and advance the program [10][13] Upcoming Catalysts - Key upcoming milestones include a Pre-Phase 3 FDA meeting, finalization of the pivotal study protocol, and initiation of the late-stage study contingent on FDA alignment and financing [19]